Redaktionell unabhängig · Wir verkaufen keine Peptide
Een onafhankelijk project uit Amsterdam, voor alle 27 EU-lidstaten

Een onafhankelijk
verslag van elke
peptide die circuleert
in Europa.

Peptidepedia catalogiseert 1.200+ verbindingen in de klassen cosmetisch, herstel, levensduur, metabool, cognitief en hormonaal — beoordeelt het bewijs achter elke claim, volgt de regelgevingsstatus in 27 jurisdicties in real-time, en publiceert kritische reportages over de merken die ze verkopen.

Verbindungen erfasst
10 · 0 diese Woche
Jurisdiktionen
27 · EU + UK + CH
Statusänderungen / 2026
0 · erfasst
REG · CATEGORY
▲ LIVE
SEQ · 0 AA
REF · —
G P L V A R Y D K SEQ · —
EU Regulatory Wire
18:42 NL CBG/MEB issues advisory on compounded GLP-1 analogues — pharmacies cited 17:30 DE BfArM tightens import controls on research peptides from third countries 15:11 FR ANSM opens consultation on Melanotan II cosmetic claims 13:58 IT AIFA confirms Semaglutide shortage extended through Q3 11:04 EU EMA publishes Annex IV update — Tirzepatide off-label monitoring 09:22 UK MHRA seizes shipments labelled BPC-157 at Heathrow 08:15 CH Swissmedic warns against online sale of CJC-1295 18:42 NL CBG/MEB issues advisory on compounded GLP-1 analogues — pharmacies cited 17:30 DE BfArM tightens import controls on research peptides from third countries 15:11 FR ANSM opens consultation on Melanotan II cosmetic claims 13:58 IT AIFA confirms Semaglutide shortage extended through Q3 11:04 EU EMA publishes Annex IV update — Tirzepatide off-label monitoring 09:22 UK MHRA seizes shipments labelled BPC-157 at Heathrow 08:15 CH Swissmedic warns against online sale of CJC-1295
§ 01 — DE ENCYCLOPEDIE

Elke verbinding, beoordeeld — niet verkocht.

Een referentiecatalogus. Elk item bevat structurele data, werkingsmechanisme, primaire literatuur, regelgevings­verwijzing en onze onafhankelijke bewijsklasse. We accepteren nooit betaling van fabrikanten of verkopers.
Zoek in 10 verbindingen, INN-namen, merknamen…
ZEIGT 8 / 10
# Verbindung Kategorie Evidenz EU-Status Zuletzt geprüft
001. Oxytocin
INN · oxytocinum · C₄₃H₆₆N₁₂O₁₂S₂ · MW 1007.2
 Hormonal
Endogenes Nonapeptid-Hormon · uterine glatte Muskelkontraktion, Milchejektion
S
 ZUGELASSEN 18 MAY 2026
002. Semaglutide
INN · semaglutidum · C₁₈₇H₂₉₁N₄₅O₅₉ · MW 4113.6
 Metabolisch
GLP-1-Rezeptoragonist · einmal wöchentlich subkutan
S
 ZUGELASSEN 18 MAY 2026
003. Tirzepatid
INN · tirzepatidum · C₂₂₅H₃₄₈N₄₈O₆₈ · MW 4813.5
 Metabolisch
Dualer GIP / GLP-1-Rezeptoragonist · einmal wöchentlich subkutan
S
 ZUGELASSEN 18 MAY 2026
004. Bremelanotid
INN · bremelanotidum
 Hormonal
Melanocortin (MC1R/MC3R/MC4R) Rezeptoragonist · bedarfsweise subkutan
A
 NICHT ZUGELASSEN 18 MAY 2026
005. Setmelanotid
INN · setmelanotidum
 Hormonal
MC4R-selektiver Melanocortin-Rezeptoragonist · täglich subkutan
A
 ZUGELASSEN 18 MAY 2026
006. Tesamorelin
INN · tesamorelinum
 Metabolisch
Synthetisches GHRH-Analogon · stimuliert hypophysäre GH-Freisetzung · täglich subkutan
A
 ZUGELASSEN 18 MAY 2026
007. Cagrilintid
INN · cagrilintidum
 Metabolisch
Langwirksamer Amylin-Rezeptoragonist · wöchentlich subkutan · Forschungsphase
B
 NICHT ZUGELASSEN 18 MAY 2026
008. GHK-Cu
C₁₄H₂₃CuN₆O₄ · MW 405
 Kosmetisch
Kupfergebundenes Tripeptid · Hautbarriere-Modulator, Wundheilungs-Adjuvans
B
 ZUGELASSEN 18 MAY 2026
Seite 1 / 2 — 10 Einträge indiziert
Open de volledige Encyclopedie →
§ 02 — REGULATORY

State of the Compound — 27 jurisdictions, one source of truth.

A live record of how each member state classifies, restricts, authorises or prohibits every compound in the registry. Updated within 24 hours of any official notice.
Semaglutide
GLP-1 R-Agonist · Metabolic
NL
Nederland
BE
België
DE
Deutschland
FR
France
IT
Italia
ES
España
AT
Österreich
PT
Portugal
IE
Éire
DK
Danmark
SE
Sverige
FI
Suomi
PL
Polska
CZ
Česko
SK
Slovensko
HU
Magyar.
RO
România
BG
България
EL
Ελλάδα
HR
Hrvatska
SI
Slovenija
EE
Eesti
LV
Latvija
LT
Lietuva
LU
Lux.
MT
Malta
CY
Κύπρος
CH
Schweiz +
UK
United K. +
NO
Norge +
Authorised — prescription
Restricted / supply controls
Prohibited / not authorised
Unclassified
Status changelog
Updating
14 MAY · 09:22
NL
BPC-157 — promotional claimsCBG/MEB orders three webshops to halt “tendon recovery” marketing pending Article 86 review.
DOWNGRADE
12 MAY · 16:08
DE
Tirzepatide — supply restoredBfArM lifts dispensing restriction following resolution of Eli Lilly supply notice 04/26.
UPGRADE
09 MAY · 11:44
FR
Melanotan II — cosmetic banANSM publishes Décret 2026-318 prohibiting Melanotan II in leave-on cosmetic products. In force 01.07.2026.
PROHIBIT
07 MAY · 14:30
EU
Annex IV — GLP-1 monitoringEMA expands post-authorisation monitoring to compounded analogues. National authorities notified.
REVISION
03 MAY · 08:50
UK
BPC-157 — border seizureMHRA reports seven shipments seized at Heathrow LHR-7. Mislabelled as “cosmetic raw materials”.
ENFORCEMENT
28 APR · 19:12
CH
CJC-1295 — public warningSwissmedic issues consumer warning following adverse event cluster, four hospitalisations.
WARNING
22 APR · 10:05
ES
GHK-Cu — cosmetic clarificationAEMPS confirms inclusion as cosmetic ingredient at concentrations ≤ 0.05% — no marketing-authorisation required.
CLARIFY
18 APR · 14:48
BE
Selank — schedule review openedFAGG/AFMPS opens public consultation on scheduling of synthetic tuftsin analogues. Closes 30 June 2026.
CONSULT
§ 03 — METHODE

Een bewijsklasse voor elke claim.

We beoordelen verbindingen op de kracht, onafhankelijkheid en replicatie van het bewijs dat hun gepromote gebruik ondersteunt — niet op de vraag of ze in principe "werken".
3 verbindingen
S
Versorgungsstandard
Meerdere hoogwaardige, onafhankelijke RCT's. Geautoriseerd door EMA of nationale instantie. Gevestigd mechanisme.
3 verbindingen
A
Stark
≥2 voldoende krachtige RCT's bij mensen met consistente effectgrootte. Plausibel mechanisme. Geen tegensprekende data van betekenis.
4 verbindingen
B
Mäßig
Eén voldoende krachtige humane studie, plus ondersteunende in-vitro / dier-data. Effect plausibel, nog niet gerepliceerd.
0 verbindingen
C
Begrenzt
Alleen pilot- of open-label humane data. Of sterke preklinische evidentie zonder klinische vertaling. Voorzichtigheid geboden.
0 verbindingen
D
Anekdotisch
Geen klinisch bewijs. Gebruikersmeldingen, forumdata, claims van verkopers. Mechanisme kan speculatief of geëxtrapoleerd zijn.
0 verbindingen
F
Widerlegt
Hoogwaardige studie(s) hebben het geclaimde effect niet kunnen aantonen, of bekende schade weegt zwaarder dan het gepromote voordeel.
Redactionele noot — financiering & methodologie

De methodologie is publiek gedocumenteerd zodat lezers elke beoordeling kunnen toetsen aan haar bronartikelen. Wij accepteren geen geld van fabrikanten, importeurs, compounding-apothekers, telezorgklinieken of peptide-verkopers; we voeren geen affiliate-links, gesponsorde content of betaalde plaatsingen.

§ 04 — BRAND DOCKET

Critical, scored reviews — without affiliate links.

We assess every brand selling into the European market on quality of evidence, claims discipline, supply-chain transparency, regulatory compliance, and customer recourse.
Issue 042 · LEAD REVIEW AVOID
Helios Bioactives — Rotterdam
2.1/ 10
Editor
M. van Doorn
“Three of the seven products we tested contained less than 60% of the labelled peptide content. Two contained a different compound altogether. The company refused our request for a Certificate of Analysis.”
Evidence claims
D · overreach
Lab purity
38–94%
Reg. compliance
3 / 12
Ships to
EU + UK + CH
Tested
7 products
Read
Full dossier →
Cosmetic peptides CLEARED
Nordlys Skin Lab
7.8/ 10
“Disciplined claims, third-party COAs published, no off-label suggestion.”
Evidence
B · honest
Compliance
11 / 12
Read
Review →
Metabolic compounding WATCH
Stadtklinik Apotheke
5.2/ 10
“Operates within compounding exemption, but volume and marketing reach raise questions about Article 5(1) reliance.”
Compounding
Active
Compliance
7 / 12
Read
Review →
Online retail AVOID
PeptideLab.eu
1.4/ 10
“Sells unapproved compounds with explicit therapeutic claims. Refused all correspondence over six months.”
Reg. flags
11 active
Compliance
0 / 12
Read
Dossier →
Recovery clinic WATCH
Atlas Performance
4.6/ 10
“Clinically supervised but routinely prescribes Grade-C compounds with overstated mechanism claims.”
Supervision
MD + RN
Claims
Overstated
Read
Review →
§ 05 — INVESTIGATIONS

The reporting nobody selling these has incentive to fund.

Long-form investigative pieces — six to twelve weeks of work each — drawing on freedom-of-information requests, lab testing, and direct interviews.
[ EDITORIAL PHOTO · Rotterdam port, container inspection ] Cover · 6 weeks reporting
Investigation · 4-part series

How “research-only” peptides reach 40,000 European customers a month — and the Rotterdam pharmacy that supplies most of them.

Six weeks of port records, supplier interviews and independent assay testing reveal a supply chain hiding in plain sight inside the EU's compounding exemption. We name the importers, the broker, and the compounding pharmacy at the centre.

By M. van Doorn, S. Klein · 4,800 words Read part one →
[ DOCUMENT IMAGE · annotated COA ] Lab assays
Field test

We tested every “BPC-157” sold to Dutch consumers. Half were something else.

Independent HPLC-MS testing of 22 products purchased anonymously. Four contained no peptide at all.

L. Aydın · 2,100 words →
[ DIAGRAM · GLP-1 supply network ] Data piece
Data investigation

The German compounding loophole keeping cheap GLP-1 alive — for now.

How §13 AMG creates a legal shelter that the EMA is no longer willing to defend in court.

P. Reuter · 3,400 words →
★ THE COMPOUND — Weekly briefing

The week's regulatory changes,
graded studies, and brands
worth your attention — in one email.

Friday mornings. Six minutes to read. Every status change in the EU + UK + CH, two new compound entries, the studies our editors thought mattered, and one investigation update. Free to read.

Subscribers
42,308 EU + UK
Open rate
68% 52-wk avg.
Editions sent
112 since Mar 2024
NO ADS · NO TRACKING · NO AFFILIATE LINKS · UNSUBSCRIBE IN ONE CLICK